文献速递白血病造血干细胞移植与细胞治疗

CD22 CAR-T细胞治疗儿童及年轻成人B细胞急性淋巴细胞白血病的十年经验

Ten-year experience of CD22 CAR T cells for children and young adults with B-cell acute lymphoblastic leukemia.
PubMed 文献 · Blood Adv · 2026-01-01

该研究总结2014年起CD22 CAR-T治疗78例B细胞急性淋巴细胞白血病患者的十年经验,第28天完全缓解率70.1%,中位总生存13.6个月,中位无复发生存6.1个月,并描述细胞因子释放综合征等毒性及药代动力学特征。

要点

  • 78例中细胞因子释放综合征66例(84.6%),IEC-HS 28例(35.9%),可逆性神经毒性18例(23.1%)。
  • 第28天完全缓解54例(70.1%),其中可测量残留病阴性45例(83.3%)。
  • 中位总生存13.6个月,中位无复发生存6.1个月。

核心结论

  • CD22 CAR-T细胞在B细胞急性淋巴细胞白血病中显示疗效,毒性、扩增和缓解与基线疾病负荷不相关。
  • 该十年经验为靶向CD22的新方法及双靶点策略提供基础,并提示减轻IEC-HS严重程度的早期干预值得进一步研究。

研究设计与样本

  • 单中心十年经验总结,纳入78例接受CD22 CAR-T输注的B细胞急性淋巴细胞白血病儿童及年轻成人患者。
  • 试验注册号NCT02315612。

主要发现

  • 细胞因子释放综合征见于66例(84.6%),IEC-HS见于28例(35.9%),可逆性神经毒性见于18例(23.1%)。
  • 第28天完全缓解54例(70.1%),其中可测量残留病阴性45例(83.3%)。
  • 中位总生存13.6个月,中位无复发生存6.1个月。
  • CAR-T细胞扩增峰值中位时间为14天(范围12-50天),不随剂量变化。
  • 毒性、CAR-T细胞扩增和疾病缓解与基线疾病负荷不相关。

临床怎么用

  • CD22 CAR-T可作为B细胞急性淋巴细胞白血病的治疗选择,需管理细胞因子释放综合征、IEC-HS和神经毒性。
  • 早期干预减轻IEC-HS严重程度在该构建体中显示前景,但需进一步研究。

局限性

  • 早期干预减轻IEC-HS严重程度的方法尚需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In 2014, the first patient received a CD22 chimeric antigen receptor (CAR) T-cell product. As one of the earliest approaches targeting an antigen other than CD19, this trial addressed an unmet need while providing insights into CAR T-cell efficacy, impact of manufacturing changes, and management of inflammatory toxicities over its 10-year span. This final chapter provides a comprehensive review of the collective findings. Across 78 patients with B-cell acute lymphoblastic leukemia who received infusion, cytokine release syndrome was observed in 66 (84.6%) patients, whereas 28 (35.9%) had immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS), and 18 (23.1%) had reversible neurotoxicity. Complete response was achieved in 54 (70.1%) patients by day 28, of whom 45 (83.3%) were measurable residual disease negative. Median overall survival was 13.6 months, and median relapse-free survival was 6.1 months. Pharmacokinetics revealed peak CAR T-cell expansion at a median of 14 days (range, 12-50), with no variation by dose. Interestingly, toxicities, CAR T-cell expansion, and disease response did not correlate with baseline disease burden. Additionally, although early intervention approaches to mitigate IEC-HS severity for this construct appeared promising, further study is needed. Given the critical importance of CD22 targeting, this experience serves as a foundation for new approaches targeting CD22 while providing ongoing support for dual-targeting approaches and insights into toxicity mitigation. This trial was registered at www.ClinicalTrials.gov as NCT02315612.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Dreyzin A, Yates B, Shalabi H, et al. Ten-year experience of CD22 CAR T cells for children and young adults with B-cell acute lymphoblastic leukemia. Blood Adv. 2026. PMID: 41411486. doi:10.1182/bloodadvances.2025017753

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。